Results 131 to 140 of about 241,963 (315)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials [PDF]

open access: gold, 2023
Ian N Bruce   +5 more
openalex   +1 more source

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify noninvasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin   +11 more
wiley   +1 more source

Dexamethasone and IFN-γ primed mesenchymal stem cells conditioned media immunomodulates aberrant NETosis in SLE via PGE2 and IDO [PDF]

open access: green
Khushbu Priya   +8 more
openalex   +1 more source

Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypes

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. Variable copy number (CN) of C4 genes and retroviral HERV‐K element influence its function.
Javier Martínez‐López   +23 more
wiley   +1 more source

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study

open access: yesJournal of Inflammation Research, 2020
Aly A Yousef,1 Faisal Y Mohamed,2 Naglaa F Boraey,3 Nagwa E Akeel,4 Attia A Soliman,4 Nevin M Waked,5 Mustafa IA Hashem,4 Hassan Shehata,4 Dalia S Fahmy,6 Ali Ismael,7 Lamya M Ibrahim,8 Mohamed AM Ibrahim,9 Hanan F Salem,10 Sherif M Yousry,11 Sherif F ...
Yousef AA   +20 more
doaj  

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama   +16 more
wiley   +1 more source

COVID-19 or systemic lupus erythematosus: Attention to similarity

open access: yesRomanian Journal of Laboratory Medicine
Arthralgia, myalgia, acute interstitial pneumonia-like presentation, venous thromboembolism, cytopenia, secondary hemophagocytic lymphohistiocytosis and cytokine storm are the clinical and laboratory findings associated with Coronavirus disease (COVID-19)
Erden Abdulsamet   +9 more
doaj   +1 more source

Prothrombotic Activation of Platelet Pannexin‐1 Channels in Antiphospholipid Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired ...
Bruna de Moraes Mazetto Fonseca   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy